(Q28301752)

https://api.crossref.org/works/10.1113/EXPPHYSIOL.2004.028522

Cloning and characterization of a secreted form of angiotensin-converting enzyme 2

20 April 2017

1 reference

https://api.crossref.org/works/10.1113/EXPPHYSIOL.2004.028522

Biological functions of angiotensin and its receptors

20 April 2017

1 reference

https://api.crossref.org/works/10.1113/EXPPHYSIOL.2004.028522

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

20 April 2017

1 reference

https://api.crossref.org/works/10.1113/EXPPHYSIOL.2004.028522

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

20 April 2017

1 reference

https://api.crossref.org/works/10.1113/EXPPHYSIOL.2004.028522

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

20 April 2017

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

20 April 2017

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

20 April 2017

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Patients' decisions about whether or not to take antihypertensive drugs: qualitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Angiotensin-converting enzyme 2 is an essential regulator of heart function

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Essential hypertension, metabolic disorders, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

The burden of adult hypertension in the United States 1999 to 2000: a rising tide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Large-scale production of retroviral vectors for systemic gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Gene therapy attenuates the elevated blood pressure and glucose intolerance in an insulin-resistant model of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Angiotensin II stimulates calcium and nitric oxide release from Macula densa cells through AT1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Hypertension as a complex genetic trait

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Endothelial-independent prevention of high blood pressure in L-NAME-treated rats by angiotensin II type I receptor antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Clinicians and patients with hypertension: unsettled issues about compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Is hypertension an insulin-resistant state? Metabolic changes associated with hypertension and antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Blood pressure, systolic and diastolic, and cardiovascular risks. US population data

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Effects of angiotensin-(1-7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Elevated blood pressure in normotensive rats produced by 'knockdown' of the angiotensin type 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Epidemiology of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Intracisternal administration of Angiotensin II AT1 receptor antisense oligodeoxynucleotides protects against cerebral ischemia in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Linkage disequilibrium analysis of the renin-angiotensin system genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Angiotensin-(1-7) inhibits angiotensin II-induced signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522

Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1113%2FEXPPHYSIOL.2004.028522